Nateglinide
生产企业:Dr reddys laboratories ltd, Par pharmaceutical inc,另有 2 家
Nateglinide is a meglitinide used to treat non insulin dependent diabetes mellitus.
Nateglinide is a meglitinide used to treat non insulin dependent diabetes mellitus.
Nateglinide activity is dependent on the presence functioning β cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic β cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue.
For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.
共 1 项相关疾病
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。